

Supplemental Information Disclosure Statement

Applicants bring to the Examiner's attention U.S. Patent No. 6,593,368, which issued from parent U.S. patent application no. 09/463,116 on July 15, 2003. A copy of U.S. Patent No. 6,593,368 is provided with the enclosed Supplemental Information Disclosure Statement.

Applicants also bring to the Examiner's attention co-pending U.S. patent application no. 10/407,888, filed April 4, 2003. The currently pending claims in U.S. patent application no. 10/407,888 are directed to combinations of gabapentin or pregabalin with a COX-2 inhibitor, including celecoxib, pharmaceutical compositions comprising said combinations, and methods of alleviating pain with said pharmaceutical compositions.

Applicants also bring to the Examiner's attention the enclosed Supplemental Information Disclosure Statement on Form PTO-1449, which cites WO 87/01036; WO 89/05642; WO 98/07447; US 6,057,373; US 6,451,857; US 6,593,368; and Rosner et al. Applicants also bring to the Examiner's attention the references cited in the four page Information Disclosure Statement ("IDS") in parent Application USSN 09/463,116. A copy of the IDS from the parent application was submitted with Applicants' first IDS in the instant application.

The Examiner is respectfully requested to consider carefully the references cited above and in the instant Supplemental IDS and the IDS from the parent application in connection with the examination of the above-identified application in accord with 37 CFR § 1.104(a). It is believed the Examiner will concur with Applicant's belief that the subject matter presently claimed is neither claimed in nor obvious from these references.

It is further respectfully requested that the references listed on the enclosed Form PTO-1449 be included in the "References Cited" portion of any patent issuing from this application (MPEP § 1302.12).